Releases

Date	Title and Summary
Nov 07, 2018 7:42 AM CET Corporate Releases	Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised
Oct 25, 2018 10:34 AM EDT Corporate Releases	Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia
Sep 28, 2018 3:30 AM EDT Corporate Releases	Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
Aug 08, 2018 5:09 AM UTC Corporate Releases	Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS
Jul 02, 2018 8:41 AM CEST Corporate Releases	Dr. Deborah Dunsire named new President and CEO of Lundbeck
Jun 25, 2018 7:00 AM CEST Press Releases	Lundbeck starts clinical development of potential new treatment of Parkinson's disease
Jun 08, 2018 5:24 PM CEST Corporate Releases	Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
Jun 06, 2018 8:56 PM CEST Corporate Releases	Lundbeck reaches voluntary agreement in principle with U.S. Department of Justice
May 23, 2018 11:22 AM CEST Corporate Releases	Lundbeck increases its share capital by 41,946 shares (0.0211 % of outstanding shares) as a result of exercise of employee warrants
May 22, 2018 1:45 AM CEST Press Releases	Lundbeck divests preclinical research programs

Choose region and then country